Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Bronchogenic

Explore clinical trials studying Carcinoma, Bronchogenic. Study availability and eligibility vary by location and protocol.

5,248 public trials 1,189 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Bronchogenic trial results

Completed

Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00660816

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Wayne State University Detroit, Michigan, United States
  • Columbia Presbyterian New York, United States
  • Lake/University Ireland Cancer Center Cleveland, Ohio, United States
  • Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States
View all 13 locations
View Trial Details
Completed

A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

NCT00743938

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Yale University School Of Medicine New Haven, Connecticut, United States
  • Hematology Oncology, P.C. Stamford, Connecticut, United States
  • Mass General Hospital Boston, Massachusetts, United States
  • Henry Ford Hospital Detroit, Michigan, United States
View all 30 locations
View Trial Details
Completed

Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response

NCT01167244

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Local Institution Kashiwa-Shi, Chiba, Japan
  • Local Institution Osaka-Sayama-Shi, Osaka, Japan
  • Local Institution Sunto-Gun, Shizuoka, Japan
  • Local Institution Koto-Ku, Tokyo, Japan
View Trial Details
Completed

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

NCT00769067

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +12 more
Locations
  • Northwest Alabama Cancer Center Muscle Shoals, Alabama, United States
  • Agajanian Institute of Oncology and Hematology Montebello, California, United States
  • Bridgeport Hospital Bridgeport, Connecticut, United States
  • Wittingham Cancer Center @ Norwalk Hospital Norwalk, Connecticut, United States
View all 59 locations
View Trial Details
Completed

Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib

NCT00993499

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations
  • 1200.70.34001 Boehringer Ingelheim Investigational Site Badalona (Barcelona), Spain
  • 1200.70.34008 Boehringer Ingelheim Investigational Site Barcelona, Spain
  • 1200.70.34009 Boehringer Ingelheim Investigational Site Barcelona, Spain
  • 1200.70.34006 Boehringer Ingelheim Investigational Site Girona, Spain
View Trial Details
Completed

Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer

NCT01090011

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations
  • 1200.71.1004 Boehringer Ingelheim Investigational Site Aurora, Colorado, United States
  • 1200.71.1003 Boehringer Ingelheim Investigational Site New Haven, Connecticut, United States
  • 1200.71.1001 Boehringer Ingelheim Investigational Site New York, United States
  • 1200.71.1002 Boehringer Ingelheim Investigational Site Nashville, Tennessee, United States
View Trial Details

Related conditions